ストックスクリーナーアプリを入手
1.165
4.69%
0.055
前日終値:
$1.11
開ける：
$1.12
24時間の取引高:
857.31K
Relative Volume:
1.03
時価総額：
$102.84M
収益：
-
当期純損益:
$-27.99M
株価収益率:
-2.4526
EPS:
-0.475
ネットキャッシュフロー:
$-29.53M
1週間 パフォーマンス:
+7.60%
1か月 パフォーマンス:
+0.18%
6か月 パフォーマンス:
-12.62%
1年 パフォーマンス:
+163.16%
1日の値動き範囲:
$1.09
$1.20
1週間の範囲:
$1.0501
$1.20
52週間の値動き範囲:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
名前
Cognition Therapeutics Inc
セクター
電話
412-481-2210
住所
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.165 | 97.98M | 0 | -27.99M | -29.53M | -0.475 |
VRTX
Vertex Pharmaceuticals Inc
|
455.43 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.53 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.68 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 開始されました | B. Riley Securities | Buy |
| 2021-11-03 | 開始されました | Oppenheimer | Outperform |
Cognition Therapeutics Inc (CGTX) 最新ニュース
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress - TipRanks
Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial By Investing.com - Investing.com India
COGNITION THERAPEUTICS ($CGTX) Releases Q4 2025 Earnings - Quiver Quantitative
Cognition Therapeutics 10-K: Net loss $23.5M, EPS $(0.32) - TradingView
Cognition Therapeutics (NASDAQ: CGTX) narrows 2025 loss, funds into Q2 2027 - Stock Titan
No approved DLB psychosis drugs; Cognition maps FDA path for one - Stock Titan
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Cognition Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia With Lewy Bodies - Neurology Live
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - The Globe and Mail
Cognition Therapeutics sets March 26 webcast on 2025 results - Stock Titan
Cognition presents data on dementia drug zervimesine at conference By Investing.com - Investing.com South Africa
CGTX PE Ratio & Valuation, Is CGTX Overvalued - Intellectia AI
Cognition presents data on dementia drug zervimesine at conference - Investing.com
Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - Bitget
Cognition Therapeutics Presents Promising Phase 2 Results of Zervimesine for Dementia with Lewy Bodies at AD/PD 2026 Conference - Quiver Quantitative
Cognition Therapeutics Presents Evidence of Zervimesine’s - GlobeNewswire
Dementia trial drug slowed neuropsychiatric decline 86% vs placebo - Stock Titan
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga Japan
Aug Intraday: Can Cognition Therapeutics Inc lead its sector in growthQuarterly Risk Review & Safe Entry Point Identification - baoquankhu1.vn
MACD Signal: What is the dividend yield of Cognition Therapeutics IncDividend Hike & AI Based Trade Execution Alerts - baoquankhu1.vn
Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia
Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget
Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks
Cognition Therapeutics, Inc. Announces Advancement of Zervimesine Development for Dementia with Lewy Bodies Psychosis Treatment - Quiver Quantitative
Cognition Therapeutics advancing zervimesine (ct1812) for dementia with Lewy bodies (DLB) psychosis - marketscreener.com
Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes - TradingView
Cognition Therapeutics Advancing Zervimesine (Ct1812) For Dementia With Lewy Bodies (DLB) Psychosis - TradingView
Zervimesine push: Cognition Therapeutics (NASDAQ: CGTX) targets DLB psychosis - Stock Titan
DLB psychosis often untreated — zervimesine study targets hallucinations - Stock Titan
CGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
COGNITION THERAPEUTICS, INC. (CGTX) Stock, Price, News, Quotes, Forecast and Insights - MSN
Can Cognition Therapeutics Inc disrupt its industryQuarterly Profit Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Is Cognition Therapeutics Inc. stock a safe buy before earningsWeekly Trend Report & High Conviction Trade Alerts - mfd.ru
Whale Trades: Is Cognition Therapeutics Inc stock heavily shortedPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
CGTX (CGTX) CFO reports tax-withholding share disposition on RSU vesting - Stock Titan
Is Cognition Therapeutics Inc. stock overvalued by current metrics2025 Key Highlights & High Win Rate Trade Alerts - mfd.ru
Why Cognition Therapeutics Inc. stock is recommended by analysts2025 Market WrapUp & Reliable Volume Spike Alerts - mfd.ru
FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M - Defense World
Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M - MarketBeat
Brookline Capital Management Predicts CGTX FY2025 Earnings - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management - Defense World
Cognition Therapeutics extends expanded access program for Zervimesine (CT1812) in dementia with Lewy bodies - marketscreener.com
Cognition Therapeutics rises as it extends access to rare brain disorder drug - TradingView
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics (NASDAQ:CGTX) Raised to "Strong-Buy" at Brookline Capital Management - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Shares Up 4.6% – Still a Buy? - Defense World
Analyst Calls: Is Cognition Therapeutics Inc. stock a safe buy before earnings2025 Top Gainers & Precise Entry and Exit Recommendations - mfd.ru
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug - Investing.com India
Cognition Therapeutics Inc (CGTX) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):